__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Indication: KESIMPTA is indicated for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.1,2
The tool below can be used to find out how patients with relapsing forms of multiple sclerosis (RMS) with active disease can be switched to KESIMPTA from other treatments. Simply click on the arrow next to the name of your patient’s current treatment to learn more about what to consider to initiate them on KESIMPTA. The information below for non-Novartis products is based on the respective product’s SmPC.
In the ASCLEPIOS I and II trials treatment-naïve patients and patients previously treated with a range of disease-modifying treatments were included.3 For further information click here.
When initiating ofatumumab after other immunosuppressive therapies with prolonged immune effects, the duration and mode of action of these medicinal products should be taken into account because of potential additive immunosuppressive effects. Patients in a severely immunocompromised state must not be treated until the condition resolves. It is not recommended to use other immunosuppressants concomitantly with ofatumumab except corticosteroids for symptomatic treatment of relapses.
Prescribing information for KESIMPTA▼ (ofatumumab) and adverse event reporting details can be found here.
Prescribing information for EXTAVIA (interferon beta) and adverse event reporting details can be found here.
Prescribing information for GILENYA (fingolimod) and adverse event reporting details can be found here.
This tool is presented for information purposes and guidance only; individual product SmPCs should be consulted as required. Novartis make no treatment recommendations; treatment decisions are the responsibility of the prescribing HCP.
RMS, relapsing forms of multiple sclerosis.
References
- KESIMPTA (ofatumumab) [Summary of Product Characteristics]. Great Britain: Novartis Pharmaceuticals UK Ltd; August 2023.
- KESIMPTA (ofatumumab) [Summary of Product Characteristics]. Novartis Ireland Limited; March 2023.
- Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. New Engl J Med. 2020;383:547–557.
